CCL2 and cancer: Inhibition of galectin-1 in CAF decreases the expression of monocyte chemotactic protein-1 (MCP-1/CCL2), which has been implicated in contributing to an immunosuppressive TME, and as an inducer of cancer progression [15, 16].